Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...
As HR's strategic role evolves, people professionals must leverage tech alongside human skills to drive success, says BVI ...
The Global Capability Centres wave is well underway in India, and the country has an opportunity to become a trusted partner ...
Straight from the mouths of cardiologists and a heart health nutritionist.
Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...
The move will provide funds to advance ETX101, a gene therapy the company is developing for SCN1A-positive Dravet syndrome, among other programs.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...
The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.